Gilead Sciences has acquired Interius BioTherapeutics for $350 million, gaining a platform for in vivo CAR-T cell therapies. This single-shot approach potentially allows genetic modification of immune cells inside the patient, avoiding ex vivo cell processing complexities. The acquisition marks Gilead's entry into in vivo cell therapies, following similar moves by major pharmaceutical companies, and could enhance the accessibility and scalability of CAR-T treatments for cancer.